Skip to main content

Advertisement

SpringerLink
Log in

Is pentraxin 3 a biomarker, a player, or both in the context of coronary atherosclerosis and metabolic factors?

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

The objective of this study is to determine whether pentraxin-3 (PTX-3) is clinically a biomarker of inflammation, a player in anti-inflammation, or both with regard to coronary atherosclerosis, we compared levels of PTX-3 with levels of adiponectin in addition to high-sensitivity C-reactive protein (hs-CRP). We enrolled 693 patients (51 % male; mean age 64 ± 12 years) at Fukuoka University Hospital. They were clinically suspected to have coronary artery disease (CAD) or had at least one cardiac risk factor and had undergone coronary computed tomography angiography (CTA). We evaluated the levels of PTX-3, hs-CRP, and adiponectin, the presence of CAD or metabolic factors, subcutaneous fat area, visceral fat area (VFA) and lipid profiles. The presence of CAD was independently associated with aging (p = 0.010) and the prevalence of hypertension (p < 0.0001), but not the levels of PTX-3, hs-CRP and adiponectin by a multivariate analysis. Although the number of significantly stenosed coronary vessels (VD) was not associated with PTX-3 or adiponectin, hs-CRP tended to increase as the number of VD increased. In addition, PTX-3 decreased as the number of metabolic factors increased, whereas hs-CRP increased as the number of metabolic factors increased. Interestingly, PTX-3 did not correlate with hs-CRP, but was positively correlated with adiponectin. In a multiple regression analysis, adiponectin (p = 0.003) and VFA (p = 0.008) were significant predictors of PTX-3 levels. In conclusion, PTX-3 and adiponectin showed similar associations with metabolic factors, whereas PTX-3 and hs-CRP showed opposite trends. Adiponectin and VFA were significant predictors of PTX-3 levels. PTX-3 might have an atheroprotective role as well as serving as a simple biomarker, like adiponectin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Knoflach M, Kiechl S, Mantovani A, Cuccovillo I, Bottazzi B, Xu Q, Xiao Q, Gasperi A, Mayr A, Kehrer M, Willeit J, Wick G (2012) Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY studies. PLOS One 7:e31474

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Arao K, Fujiwara T, Taniguchi Y, Jinnouchi H, Sasai H, Matsumoto M, Funayama H, Ako J, Momomura SI (2014) Implications of pentraxin 3 levels in patients with acute aortic dissection. Heart Vessels. doi:10.1007/s00380-014-0470-2

    Google Scholar 

  3. Soeki T, Bando S, Uematsu E, Matsuura T, Niki T, Ise T, Kusunose K, Hotchi J, Ueda Y, Tomita N, Yamaguchi K, Yagi S, Fukuda D, Taketani Y, Iwase T, Yamada H, Wakatsuki T, Shimabukuro M, Sata M (2013) Pentraxin 3 is a local inflammatory marker in atrial fibrillation. Heart Vessels. doi:10.1007/s00380-013-0400-8

    Google Scholar 

  4. Mantovani A, Garlanda C, Bottazzi B (2003) Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 21:S2/43–S2/47

  5. Norata GD, Marchesi P, Venu VKP, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL (2009) Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120:699–708

    Article  CAS  PubMed  Google Scholar 

  6. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Oushi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89

    Article  CAS  PubMed  Google Scholar 

  7. Nishida M, Moriyama T, Sugita Y, Yamauchi-Takihara K (2007) Abdominal obesity exhibits distinct effect on inflammatory and anti-inflammatory proteins in apparently healthy Japanese men. Cardiovasc Diabet 6:27

    Article  Google Scholar 

  8. Ohashi N, Yamamoto H, Horiguchi J, Kitagawa T, Hirai N, Ito K, Kohno N (2009) Visceral fat accumulation as a predictor of coronary artery calcium as assessed by multislice computed tomography in Japanese patients. Atherosclerosis 202:192–199

    Article  CAS  PubMed  Google Scholar 

  9. Lee Y, Lee S-H, Jung E-S, Kim J-S, Shim CY, Ko Y-G, Choi D, Jang Y, Chung N, Ha J-W (2010) Visceral adiposity and the severity of coronary artery disease in middle-aged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1. Atherosclerosis 213:592–597

    Article  CAS  PubMed  Google Scholar 

  10. Tommasi S, Carluccio E, Bentivoglio M, Buccolieri M, Mariotti M, Politano M, Corea L (1999) C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol 83:1595–1599

    Article  CAS  PubMed  Google Scholar 

  11. Mitsutake R, Miura S, Kawamura A, Saku K (2009) Are metabolic factors associated with coronary artery stenosis on MDCT? Circ J 73:132–138

    Article  PubMed  Google Scholar 

  12. Patel SS, Kimmel PL, Singh A (2002) New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI. Semin Nephrol 22:449–458

    PubMed  Google Scholar 

  13. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR serum creatinine in Japan. Am J Kidney Dis 53:982–992

    Article  CAS  PubMed  Google Scholar 

  14. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143

    Article  CAS  PubMed  Google Scholar 

  15. Parfyonova Y, Alekseeva I, Plekhanova O, Deev A, Titaeva E, Dobrovolsky A, Gabbasov Z, Lyakishev A, Tkachuk V (2013) Plasma urokinase antigen and C-reactive protein predict angina recurrence after coronary angioplasty. Heart Vessels. doi:10.1007/s00380-013-0407-1

    PubMed  Google Scholar 

  16. Meuwissen M, Winter RJ, Chamuleau SAJ, Heijne M, Koch KT, Berg A, Straalen JP, Matthijs Bax, Schorborgh CE, Kearney D, Sanders GT, Tijssen JGP, Piek JJ (2003) Value of C-reactive protein in patients with stable angina pectoris, coronary narrowing (30% to 70%), and normal fractional flow reserve. Am J Cardiol 92:702–705

    Article  CAS  PubMed  Google Scholar 

  17. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL (2002) C-reactive protein and angiographic coronary artery disease: Independent and Additive predictors of risk in subjects with angina. J Am Coll Cardiol 39:632–637

    Article  CAS  PubMed  Google Scholar 

  18. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, Kurata T, Ota H, Mantovani A, Hamakubo T, Daida H, Kodama T (2007) Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Artherioscler Thromb Vasc Biol 27:161–167

    Article  CAS  Google Scholar 

  19. Matsuura Y, Hatakeyama K, Imamura T, Tsuruda T, Shibata Y, Kodama T, Kitamura K, Asada Y (2012) Different distribution of pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques. J Atheroscler Thromb 19:837–845

    Article  CAS  PubMed  Google Scholar 

  20. Ogawa T, Kawano Y, Imamura T, Kawakita K, Sagara M, Matsuo T, Kakitsubata Y, Ishikawa T, Kitamura K, Hatakeyama K, Asada Y, Kodama T (2010) Reciprocal contribution of petraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity 18:1871–1874

    Article  CAS  PubMed  Google Scholar 

  21. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131–2135

    Article  CAS  PubMed  Google Scholar 

  22. Miyamoto T, Qureshi AR, Heimbürger O, Bárány P, Carrero K, Sjöberg B, Lindholm B, Stenvinkel P, Carrero JJ (2011) Inverse relation between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol 6:2785–2791

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K, Shirahata A, Taniyama M (2003) Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obesity Res 11:1072–1079

    Article  CAS  Google Scholar 

  24. Osorio-Conles O, Guitart M, Chacón MR, Maymo-Masip E, Moreno-Navarrete JM, Montori-Grau M, Näf S, Fernadez-Real JM, Vendrell J, Gómez-Foix AM (2011) Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. Am J Physiol Endocrinol Metab 301:E1254–E1261

    Article  CAS  PubMed  Google Scholar 

  25. Miyaki A, Maeda S, Choi Y, Akazawa N, Tanabe Y, Ajisaka R (2012) Habitual aerobic exercise increase plasma petraxin 3 levels in middle-aged and elderly women. Appl Physiol Nutr Metab 37:907–911

    Article  CAS  PubMed  Google Scholar 

  26. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, Garlanda C, Mantovani A, Catapano AL (2008) Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Atherioscler Thromb Vasc Biol 28:925–931

    Article  CAS  Google Scholar 

Download references

Conflict of interest

K.S. is a Chief Director and S.M. is a Director of NPO Clinical and Applied Science, Fukuoka, Japan. K.S. is the Chairman of an Endowed Department, the “Department of Molecular Cardiovascular Therapeutics”, supported by MSD, Co. LTD. S.M. belongs to the Department of Molecular Cardiovascular Therapeutics, supported by MSD, Co. LTD.

Author information

Authors and Affiliations

  1. Department of Cardiology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan

    Ayumi Nakamura, Shin-ichiro Miura, Yuhei Shiga, Kenji Norimatsu, Yuiko Miyase, Yasunori Suematsu, Ryoko Mitsutake & Keijiro Saku

  2. Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Fukuoka, 814-0180, Japan

    Shin-ichiro Miura & Keijiro Saku

Authors
  1. Ayumi Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shin-ichiro Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuhei Shiga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenji Norimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuiko Miyase
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasunori Suematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ryoko Mitsutake
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Keijiro Saku
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shin-ichiro Miura.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, A., Miura, Si., Shiga, Y. et al. Is pentraxin 3 a biomarker, a player, or both in the context of coronary atherosclerosis and metabolic factors?. Heart Vessels 30, 752–761 (2015). https://doi.org/10.1007/s00380-014-0553-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-014-0553-0

Keywords

Search

Navigation